Astellas and Amgen Astellas’ Evenity (romosozumab) Receives MHLW Approval for Patients with Osteoporosis at High Risk of Fracture in Japan

 Astellas and Amgen Astellas’ Evenity (romosozumab) Receives MHLW Approval for Patients with Osteoporosis at High Risk of Fracture in Japan

Astellas and Amgen Astellas’ Evenity (romosozumab) Receives MHLW Approval for Patients with Osteoporosis at High Risk of Fracture in Japan

Shots:
  •  The approval from Japanese Ministry of Health is based on two P-III study FRAME &  BRIDGE assessing Evenity (210mg) vs PBO in 7,180 & 245 postmenopausal women with osteoporosis & men with osteoporosis respectively for 12 months
  • Evenity (romosozumab) 105mg IV SC is a mAb, indicated for the reduction of    osteoporosis at high risk of fracture in adults, with its MAA filling under review by the US FDA and EMA
  • Amgen Astellas’ Evenity has received its first approval worldwide and third for the    company. In 2004, Amgen and UCB collaborated to jointly develop Evenity worldwide

Click here to read full press release/ article | Ref: Amgen Astellas BioPharma| Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post